Chemistry:Donitriptan

From HandWiki
Revision as of 03:54, 6 February 2024 by Raymond Straus (talk | contribs) (link)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Donitriptan
Donitriptan.svg
Clinical data
ATC code
  • None
Legal status
Legal status
  • Never marketed
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC23H25N5O2
Molar mass403.486 g·mol−1
3D model (JSmol)

Donitriptan (INN) (code name F-11356) is a triptan drug which was investigated as an antimigraine agent but ultimately was never marketed.[1] It acts as a high-affinity, high-efficacy/near-full agonist of the 5-HT1B (pKi = 9.4–10.1; IA = 94%) and 5-HT1D receptors (pKi = 9.3–10.2; IA = 97%), and is among the most potent of the triptan series of drugs.[2][3][4] Donitriptan was being developed in France by bioMérieux-Pierre Fabre and made it to phase II clinical trials in Europe before development was discontinued.[5][6][7]

References

  1. "Donitriptan (Pierre Fabre)". Current Opinion in Investigational Drugs 2 (3): 415–418. March 2001. PMID 11575714. 
  2. "Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors". Journal of Medicinal Chemistry 38 (18): 3602–3607. September 1995. doi:10.1021/jm00018a020. PMID 7658447. 
  3. "Triptans, 5-HT1B/1D Receptor Agonists in the Acute Treatment of Migraine". The Headaches. Lippincott Williams & Wilkins. 2006. pp. 470–. ISBN 978-0-7817-5400-2. https://books.google.com/books?id=VXMI1ry9FgQC&pg=PA470. 
  4. "F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine". The Journal of Pharmacology and Experimental Therapeutics 290 (1): 83–95. July 1999. PMID 10381763. http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=10381763. 
  5. "An Overview of Current and Investigational Drugs for the Treatment of Acute and Chronic Pain". Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. CRC Press. 28 May 2013. pp. 402–. ISBN 978-0-203-91125-9. https://books.google.com/books?id=anRzslvfcUwC&pg=PA402. 
  6. Neuropsychopharmacology. Springer Vienna. 21 May 2003. pp. 38–. ISBN 978-3-211-83903-4. https://books.google.com/books?id=1ySUGaXI_wEC&pg=PA38. 
  7. "New Areas of Research". Understanding Migraine and Other Headaches. Univ. Press of Mississippi. 2004. pp. 118. ISBN 978-1-60473-048-7. https://archive.org/details/understandingmig00stew.